Longitudinal Cost of Septal Myectomy Versus Alcohol Septal Ablation for Hypertrophic Cardiomyopathy

Mayo Clin Proc. 2022 Sep;97(9):1656-1663. doi: 10.1016/j.mayocp.2022.02.014.

Abstract

Objective: To compare the postprocedural health care utilization and cost of septal myectomy (SM) and alcohol septal ablation (ASA).

Patients and methods: Using the OptumLabs Data Warehouse, we analyzed de-identified claims data of adult patients undergoing SM and ASA for obstructive hypertrophic cardiomyopathy from January 1, 2006, through December 31, 2018. We used propensity score weighting to compare the 2-year incidence rates of emergency department visits and rehospitalizations after SM and ASA.

Results: We identified 953 patients in total: 660 underwent SM and 293 underwent ASA. There was no difference in the risk (odds ratio, 1.1; 95% CI, 0.6 to 1.8) or frequency (incidence rate ratio, 1.1; 95% CI, 0.8 to 1.5) of emergency department visits, but the annual risk of hospital readmission was 10.8% after SM and 25.9% after ASA during the second postoperative year (P=.004). In those who were ever readmitted, the average length of hospital stay within the first 2 years after ASA was 1.6 times as long as that after SM (incidence rate ratio, 1.6; 95% CI, 1.0 to 2.4). Overall, the 2-year cumulative postprocedural cost was significantly higher after ASA (P<.001).

Conclusion: Compared with ASA, SM is associated with fewer hospital readmissions and lower 2-year postprocedural health care cost.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ablation Techniques*
  • Adult
  • Cardiac Surgical Procedures*
  • Cardiomyopathy, Hypertrophic* / surgery
  • Ethanol / therapeutic use
  • Humans
  • Treatment Outcome

Substances

  • Ethanol